Prognosis in UC After First Biological

Condition:   Ulcerative Colitis Intervention:   Biological: infliximab, adalimumab, golimumab, vedolizumab, ustekinumab Sponsor:   Tampere University Hospital Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials